An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

NCT03144661 | Terminated Phase 1 FDA Drug

• 2 other identifiers: INCB 62079-1012017-001153-13
• Study Type: interventional
• Target: 25
• Locations: 2 countries
• Sites: 6

Brief Summary

The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.

Conditions

Hepatocellular Carcinoma (HCC); Cholangiocarcinoma; Esophageal Cancer; Nasopharyngeal Cancer; Ovarian Cancer; Solid Tumors

Keywords

hepatocellular carcinoma; cholangiocarcinoma; esophageal; nasopharyngeal; serous ovarian; solid tumors; fibroblast growth factor (FGF); fibroblast growth factor receptor (FGFR)

Outcome Measures

Primary Outcomes (1)

• Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs)

  An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a subject provides informed consent.

  Baseline to 30-35 days after end of treatment, up to approximately 6 months per subject.

Secondary Outcomes (8)

• Objective Response Rate

  Every 2 cycles during the treatment period and every 8 weeks during the follow-up period, up to approximately 6 months per subject.

• Cmax of INCB062079

  Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject.

• Tmax of INCB062079

  Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject.

• Cmin of INCB062079

  Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject.

• AUC0-t of INCB062079

  Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject.

Study Arms (8)

Part 1 - INCB062079 10mg QD

EXPERIMENTAL

INCB062079 was administered at 10mg once daily

Drug: INCB062079

Part 1 - INCB062079 10mg BID

EXPERIMENTAL

NCB062079 was administered at 10mg twice daily

Drug: INCB062079

Part 1 - INCB062079 15mg BID

EXPERIMENTAL

NCB062079 was administered at 15mg twice daily

Drug: INCB062079

Part 1 - INCB062079 10 mg BID + BAS

EXPERIMENTAL

NCB062079 was administered at 10 mg twice daily in combination with bile acid sequestrants (BAS)

Drug: INCB062079

Part 1 - INCB062079 15 mg BID + BAS

EXPERIMENTAL

NCB062079 was administered at 15mg twice daily in combination with bile acid sequestrants (BAS)

Drug: INCB062079

Part 2 Dose Expansion - Cohort A

EXPERIMENTAL

HCC Subjects with FGF19 amplification were enrolled to evaluate the dose selected in Part 1

Drug: INCB062079

Part 2 - Dose Expansion Cohort B

EXPERIMENTAL

HCC Subjects without FGF19 amplification were enrolled to evaluate the dose selected in Part 1

Drug: INCB062079

Part 2 - Dose Expansion Cohort C

EXPERIMENTAL

Subjects with cholangiocarcinoma or esophageal, nasopharyngeal, or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration were enrolled to evaluate the dose selected in Part 1

Drug: INCB062079

Interventions

INCB062079 DRUG

In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.

Part 1 - INCB062079 10 mg BID + BAS; Part 1 - INCB062079 10mg BID; Part 1 - INCB062079 10mg QD; Part 1 - INCB062079 15 mg BID + BAS; Part 1 - INCB062079 15mg BID; Part 2 - Dose Expansion Cohort B; Part 2 - Dose Expansion Cohort C; Part 2 Dose Expansion - Cohort A

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Part 1: HCC; cholangiocarcinoma; or esophageal, nasopharyngeal, or serious ovarian cancer, regardless of FGF19/FGFR4 status; or other solid tumor malignancies with documented FGF19/FGFR4 alteration (FGF19/FGFR4 pathway activating alterations include, but are not limited to, FGFR4 amplification, FGFR4 activating mutations, and FGF19 amplification) based on local testing.
• Part 2: Subjects will be enrolled into 1 of 3 cohorts:
• Cohort A: HCC with FGF19 amplification.
• Cohort B: HCC without FGF19 amplification.
• Cohort C: cholangiocarcinoma, esophageal, nasopharyngeal or serous ovarian cancers (regardless of FGF19/FGFR4 status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.
• Has progressed after prior therapy and either a) there is no further effective standard anticancer therapy available (including subject refusal) or b) is intolerant to standard anticancer therapy.
• Life expectancy \> 12 weeks.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Part 1) or 0-2 (Part 2).
• Archival tumor specimen according to protocol-defined criteria.
• Centrally analyzed screening C4 (bile acid synthesis precursor) results must be below 40.9 ng/mL, which is the upper limit as determined by the sponsor.
• Must agree to take bile acid sequestrants while taking INCB062079.

You may not qualify if:

• Treatment with other investigational study drug for any indication for any reason, or receipt of anticancer medications within 28 days before first dose of study drug; subjects must have recovered from AEs due to previously administered therapies.
• Prior receipt of a selective FGFR4 inhibitor within the last 6 months.
• Laboratory parameters outside the protocol-defined ranges.
• History or presence of an abnormal ECG that in the investigator's opinion is clinically meaningful.
• Prior radiotherapy within 2 weeks of study treatment. A 1-week washout period is permitted for palliative radiation to non- central nervous system (CNS) disease with medical monitor approval.
• History of human immunodeficiency virus infection.
• Untreated brain or CNS metastases or brain/CNS metastases that have progressed. Subjects with previously treated and clinically stable brain/CNS metastases and who are off all corticosteroids for ≥ 4 weeks are eligible.
• Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment, except concomitant antiviral systemic therapy for chronic hepatitis B or C.
• Child-Pugh liver function Class B or C.
• History of clinically significant or uncontrolled cardiac disease.
• History of allergic reactions to INCB062079, any of the excipients of INCB062079 or similar compounds.
• Pregnant or nursing women or subjects expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 90 days after last dose of study drug.
• Any medical condition that would in the investigator's judgment interfere with full participation in the study, including administration of study medication and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.

Sponsors & Collaborators

• Incyte Corporation: lead

Study Sites (6)

University of Alabama

Birmingham, Alabama, 35294, United States

Location

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

University of Toledo Medical Center

Toledo, Ohio, 43614, United States

Location

Institut Jules Bordet

Brussels, 1000, Belgium

Location

Cliniques Universitaires Saint-Luc

Brussels, 1200, Belgium

Location

University Hospital (UZ) Leuven

Leuven, 3000, Belgium

Location

Related Publications (1)

• Harding JJ, Jungels C, Machiels JP, Smith DC, Walker C, Ji T, Jiang P, Li X, Asatiani E, Van Cutsem E, Abou-Alfa GK. First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors. Target Oncol. 2023 Mar;18(2):181-193. doi: 10.1007/s11523-023-00948-8. Epub 2023 Feb 14.

  PMID: 36787089 DERIVED

MeSH Terms

Conditions

Carcinoma, Hepatocellular; Cholangiocarcinoma; Esophageal Neoplasms; Nasopharyngeal Neoplasms; Ovarian Neoplasms; Acrocephalosyndactylia

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Esophageal Diseases; Gastrointestinal Diseases; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Nasopharyngeal Diseases; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases; Endocrine Gland Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Craniosynostoses; Synostosis; Dysostoses; Bone Diseases, Developmental; Bone Diseases; Musculoskeletal Diseases; Syndactyly; Craniofacial Abnormalities; Musculoskeletal Abnormalities; Limb Deformities, Congenital; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Luis F. Vinas, MD

  Incyte Corporation

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 5, 2017
• First Posted: May 9, 2017
• Study Start: May 25, 2017
• Primary Completion: June 10, 2020
• Study Completion: June 10, 2020
• Last Updated: October 21, 2025

Record last verified: 2025-10

Locations

US (3); BE (3)